ArticleNature medicine2025
Transplantation of a genetically modified porcine heart into a live human.
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Activating a patient-relevant pathogenic variant of a genetically defined heart disease in a humanized pig model.Lab animal · 2026Article
- Genetically Modified and Gene-Edited Organisms-Objectives, Public Perception and Applications.Biology · 2026Review
- The making of cells and organs in xenogeneic animal bioreactor.Signal transduction and targeted therapy · 2026Review
- Article
- A novel immunoglobulin G- and immunoglobulin cleaving enzyme MG (IceMG), for antibody-mediated rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Peptide hormones and bile acids shaping immune tolerance of the liver: implications and applications.Protein & cell · 2026Review
- Gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Genome-edited safe and immune-evasive human pluripotent cells: Potential solution for allogeneic therapies.Stem cell reports · 2026Article
- In vitro mimicking of humanized cardiogenesis under porcine condition.Cell & bioscience · 2026Article
- Engineering Volumetric Tissue Analogs via Assembly of Endothelial Cell-Covered Spheroidal Microtissues.Advanced healthcare materials · 2026Article
- Modern xenotransplantation: rewiring glycan-mediated immunogenicity via genome-glycome convergence.EBioMedicine · 2026Review
- Review
- Porcine xenotransplantation in the clinical era: converging advances and unresolved barriers on the path to clinical translation - a narrative review.Frontiers in immunology · 2026Review
- On the horizon in biomedical engineering.Nature biomedical engineering · 2026Article
- The CD40-CD154 axis in transplantation: from immunobiology to therapeutic targeting.Frontiers in immunology · 2026Review
- The Top 12 Most Impactful Papers in Clinical Transplantation in 2025: TI Editors' Choice.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Xenotransplantation: lessons from history, genetic engineering, and early clinical experience-an interview with Dr. David K. C. Cooper.Frontiers in transplantation · 2026Article
- T cell-mediated immune responses in xenotransplantation: mechanisms and therapeutic strategies.Frontiers in immunology · 2026Review
- Specific pathogen free ten gene-edited donor pigs for xenotransplantation.Protein & cell · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
Abstract
Following our previous experience with cardiac xenotransplantation of a genetically modified porcine heart into a live human, we sought to achieve improved results by selecting a healthier recipient and through more sensitive donor screening for potential zoonotic pathogens. Here we transplanted a 10-gene-edited pig heart into a 58-year-old man with progressive, debilitating inotrope-dependent heart failure due to ischemic cardiomyopathy who was not a candidate for standard advanced heart failure therapies. He was maintained on a costimulation (anti-CD40L, Tegoprubart) blockade-based immunomodulatory regimen. The xenograft initially functioned well, with excellent systolic and diastolic function during the first several weeks posttransplantation. Subsequently, the xenograft developed rapidly progressing diastolic heart failure, biventricular wall thickening and, ultimately, near-complete loss of systolic function necessitating initiation of extracorporeal membranous oxygenation on day 31. Given these setbacks, the patient chose to transition to comfort care after 40 days. As with our first patient, histology did not reveal substantial immune cell infiltration but suggested capillary endothelial injury with interstitial edema and early fibrosis. No evidence of porcine cytomegalovirus replication in the xenograft was observed. Strategies to overcome the obstacle of antibody-mediated rejection are needed to advance the field of xenotransplantation.
Indexed as
Identifiers
39779924What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.